DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,753,631 Paulson Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,753,631 Paulson Et Al US005753631A United States Patent (19) 11 Patent Number: 5,753,631 Paulson et al. 45) Date of Patent: May 19, 1998 54 INTERCELLULAR ADHESION MEDIATORS Tyrrell, David, et al. (1991) "Structural requirements for the carbohydrate ligand of E-selectin", Proc. Natl. Acad. Sci 75 Inventors: James C. Paulson, Sherman Oaks; USA, 88:10372-10376. Mary S. Perez, Carlsbad; Federico C. Derwent Publications Ltd., London, GB:AN 90-135674 & A. Gaeta, La Jolla; Robert M. JP-A-0283 337 (Nichirei KK) Mar. 23, 1990. Abstract. Ratcliffe, Carlsbad, all of Calif. Kannagi, Reiji, et al. (1982) "Possible role of ceramide in defining structure and function of membrane glycolipids”, 73) Assignee: Cytel Corporation, San Diego, Calif. Proc. Natl. Acad. Sci USA, 79:3470-3474. Hakomori, Sen-itiroh, et al. (1984) "Novel Fucolipids Accu (21) Appl. No.: 457,886 mulating in Human Adenocarcinoma', The Journal of Bio (22 Filed: May 31, 1995 logical Chemistry, 259(7):4672-4680. Fukushi, Yasuo, et al. (1984) "Novel Fucolipids Accumu Related U.S. Application Data lating in Human Adenocarcinoma", The Journal of Biologi cal Chemistry, 259(16):10511-10517. 60 Division of Ser. No. 63,181, May 14, 1993, which is a Holmes, Eric H., et al. (1985) Enzymatic Basis for the continuation-in-part of Ser. No. 810,789, Dec. 17, 1991, abandoned, which is a continuation-in-part of Ser. No. Accumulation of Glycolipids with X and Dimeric X Deter 716,735, Jun. 17, 1991, abandoned, which is a continuation minants in Human Lung Cancer Cells (NCI-H69), The in-part of Ser. No. 632,390, Dec. 21, 1990, abandoned, Journal of Biological Chemistry, 260(12:7619-7627. which is a continuation-in-part of Ser. No. 619,319, Nov. 28, Fukuda, Michiko N., et al. (1986) "Structure of a Novel 1990, abandoned, which is a continuation-in-part of Ser. No. Pialylated Fucosyl Lacto-N-nor-hexaosylceramide Isolated 538,853, Jun. 15, 1990, abandoned. from Chronic Myelogenous Leukemia Cells". The Journal (51) Int. Cl. ......................... A61K 31/70; CO7H 15/00 of Biological Chemistry, 261(5):2376-2383. 52 U.S. Cl. ................................... 514/25; 514/8; 514/54; McIntire, Floyd C., et al. (1988) “A polysaccharide fromn 514/61; 514/62; 536/17.2:536/18.2; 536/18.7; Streptococcus sanguis 34 that inhibits Coaggregation of S. 536/53: 536/54; 536/55; 536/55.1536/55.2 sanguis 34 with Actinomyces viscous T14V", Journal of 58 Field of Search .................................... 514/8, 25, 54, Bacteriology, 170(5:2229-2235. 514/61, 62; 536/17.2, 18.2, 18.7, 53, 54, Nilsson, Kurt G.I. (1988) "Enzymatic synthesis of oligosac 55, 55.1, 55.2 charides' Trends in Biotechnology, 6:256-264. Cassels, Frederick J. et al. (1989) “Isolation of a Coaggre (56) References Cited gation-Inhibiting Cell Wall Polysaccharide from Strepto U.S. PATENT DOCUMENTS coccus sanguis H1", Journal of Bacteriology, 171(7):4019-4025. 4,904,596 2/1990 Hakomori .............................. 435/723 Finne, Jukka, et al. (1989) “Novel Polyfucosylated 5,079,353 1/1992 Ratcliffe et al. .......................... 536/53 5296,594 3/1994 Ratcliffe et al. .......................... 536/53 N-Linked Glycopeptides with Blood Group A.H.X and Y 5,324,663 6/1994 Lowe ............... ... 435/320.1 Determinants from Human Small Intestinal Epithelial 5,344,870 9/1994 Ratcliffe et al. ....................... 52.5/54.2 Cells”, The Journal of Biological Chemistry, 5,428,025 6/1995 Brandley et al. ......................... 514/55 264(10):5720-5735. FOREIGN PATENT DOCUMENTS (List continued on next page.) 62-273.99 11/1987 European Pat. Off.. Primary Examiner-Kathleen K. Fonda WO 90/13300 11/1990 WIPO Attorney, Agent, or Firm-Townsend and Townsend and WO 91/06632 5/1991 WIPO. Crew LLP WO 91/07993 6/1991 WIPO : WO 91/19502 12/1991 WIPO. 57 ABSTRACT WO 92/07572 5/1992 WIPO The present invention is directed towards compositions and OTHER PUBLICATIONS methods for reducing or controlling inflammation and for Johnson, Philip H., et al. (1985) "Sialyl compounds as treating inflammatory disease processes and other pathologi acceptor substrates for the human ol-3-and O-3/4-L-fuco cal conditions mediated by intercellular adhesion. The com syltransferases". Biochem. Soc. Trans, 13(6):1119-1120. positions of the invention include compounds that selec Ching, C.K., et al. (1990) "Purification and Characterization tively bind selectin receptors, the selectin binding activity of a Peanut-Agglutination-Binding Pancreatic-Cancer-Re being mediated by a carbohydrate moiety. The selectin lated Serum Mucus Glycoprotein', Int, J. Cancer, binding moieties of the invention are derivatives of a 45:1022-1027. sialylated, fucosylated N-acetylactosamine unit of the Rosen, Steven D. et al. (1986) "Lymphocyte attachment to Lewis Xantigen. Compounds containing a selectin-binding high endothelial venules during recirculation: A possible moiety in both monovalent and multivalent forms are role for carbohydrates as recognition determinants', included in the invention. The compounds of the invention Molecular and Cellular Biochemistry, 72:153-164. are provided as pharmaceutical compositions which include, Underhill, Charles, et al. (1978) "The Role of Hyaluronic for example, liposomes that carry selectin-binding moieties Acid in Intercellular Adhesion of Cultured Mouse Cells”, of the invention. The invention further includes immuno Experimental Cell Research, 117:155-164. globulins capable of selectively binding an oligosaccharide Picker, Louis J., et al. (1991) "The Neutrophil Selectin ligand that is recognized by a selectin receptor. LECAM-1 Present Carbohydrate Ligands to the Vascular Selectins ELAM-1 and GMP-140". Cell 66:921-933, 9 Claims, 24 Drawing Sheets 5,753,631 Page 2 OTHER PUBLICATIONS Parmentier, Sophie, et al., "Inhibition of Platelet Functions Levery, Steven B., et al. (1988) “H-N.M.R. Analysis of by a Monoclonal Antibody (LYP20) Directed Against a Type-2 Chain Lacto-Gangliosides. Confirmation of Struc Granule Membrane Glycoprotein (GMP-140/PADGEM)”. ture of a Novel Cancer-Associated Fucoganglioside". Car Blood, 77(8):1734-1739 (1991). bohydrate Research, 178:121-144. Hakamori, et al. (1984) J. Biol. Chem, 259(7):4672–4680. Skinner, Michael P. et al., “GMP-140 Binding to Neutro Sakura (1989) Chemical Abstracts, 111:151639b. phils Is Inhibited by Sulfated Glycans”, Journal of Biologi Hansson, Gunnar, C., et al. (1983) "Mouse Monoclonal cal Chemistry, 266(9):5371-5374 (1991). Antibodies against Human Cancer Cell Lines with Specifificities for Blood Group and Related Antigens", The Goelz, Susan E., “ELFT: A Gene That Directs the Expres Journal of Biological Chemistry, 258(7):4091-4097. sion of an ELAM-1 Ligand", Cell, 63:1349-1356 (1990). Hakomori, Sen-itiroh (1985) “Aberrant Glycosylation in Cancer Cell Membranes as Focused on Glycolipids: Over Berg, Ellen L., et al., "A Carbohydrate Domain Common to view and Perspectives". Cancer Research 435:2405-2414. Both Sialyl Le(a) and Sialyl (x) is Recognized by the Yoichi, Sakurai, et al. (1989) “Production and clinical appli Endothelial Cell Leukocyte Adhesion Molecule ELAM-1”, cation of monoclonal antibodies NCC-CO-450,-473 reac Journal of Biological Chemistry, 266(23):14869-14872 tive with high-molecular-weight glycoprotein circulating in (1991). body fluid of gastrointestinal cancer patients”, (Abstract), Immunochemistry, 111:531. Lasky, Laurence A., et al., "The Lectin Cell Adhesion Hautanen, Aarno, et al. (1989) “Effects of Modifications of Molecules (LEC-CAMs): A New Family of Cell Adhesion the RGD Sequence and Its Context on Recognition by the Proteins Involved with Inflammation' Journal Cell Bio Fibronectin Receptor". The Journal of Biological Chemistry, chemistry, 45(2):139-146 (1991). 264(3):1437-1442. Eggens, Ivan, et al. (1989) "Specific Interaction Between Phillips, M. Laurie, et al. "ELAM-1 Mediates Cell Adhe Le” and Le Determinants". The Journal of Biological sion by Recognition of a Carbohydrate Ligand, Sia Chemistry, 264(16):9476-9484. lyl-Le(x)", Science, 250:1130-1132 (1990). Shitara, Kenya, et al. (1991) "Application of anti-Sialyl Le” Monoclonal antibody, KM231, for Immunotherapy of Can Picker, Louis J., et al., ELAM-1 is an adhesion molecule for cer", Anticancer Research, 11:2003-2014. skin-homing T Cells, Nature, 349:796-799 (1991). Zhou, Qun, et al. (1991) "The Selectin GMP-140 Binds to Sialylated, Fucosylated Lactosaminoglycans on Both Tiemeyer, Michael, et al., Carbohydrate ligands for endot Myeloid and Nonmyeloid Cells". The Journal of Cell Biol helial-leukocyte adhesion molecule III, Proc. Nat. Acad. ogy, 115(2):557-564. Sci., 88:1138-1142 (1991). Polley, Margaret J., et al. (1991) "CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize Shimizu, Yoji, et al., "Activation-independent binding of the same carbohydrate ligand, sialyl-Lewis x”, Proc. Natl. human memory T cells to adhesion molecule ELAM-1”, Acad, Sci, 88:6224-6228. 349:799-802 (1991). Leeuwenberg, Jet F.M., et al., “IFN-yRegulates the Expres sion of the Adhesion Molecule Elam-1 and IL-6 Production P.J. Green, et al., (1992) "High Affinity Binding of the by Human Endothelial Cells In Vitro", Journal of Immunol Leucocyte Adhesion Molecule L-Selectin to 3'-Sulphat ogy, 145:2110-2114 (1990). ed-Leand-Le” Oligosaccharides and the Predominance of Graber, Norma, et al., "T Cells Bind to Cytokine-Activated Sulphate in this Interaction Demonstrated by Binding Stud Endothelial Cells Via a Novel, Inducible Sialoglycoprotein ies with a Series of Lipid-Linked Oligosaccharides,” Bio and Endothelial Leukocyte Adhesion Molecule-1", Journal chemical and Biophysical Research Communications, of Immunology, 145:819–830 (1990). 188(1):244-251. Koch, Alisa E., et al., "Immunolocalization of endothelial and Leukocyte Adhesion Molecules in Human Rheumatoid G. Hortin, et al., (1981) "Metabolic Labeling of Lutropin and Osteoarthritic Synovial Tissues", Laboratory Investiga with SI sulfate.” Proc. Natl. Acad. Sci. USA tion, 64 (3): 313-320 (1991). 78(2):7468-7472. Osborn, Laurelee, "Leukocyte Adhesion to Endothelium in Inflammation".
Load more

Recommended publications
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • Evaluation of Signaling Pathways Profiling in Human Dermal
    toxins Article Evaluation of Signaling Pathways Profiling in Human Dermal Endothelial Cells Treated by Snake Venom Cysteine-Rich Secretory Proteins (svCRiSPs) from North American Snakes Using Reverse Phase Protein Array (RPPA) Montamas Suntravat 1,2,* , Oscar Sanchez 1, Armando Reyes 1, Abcde Cirilo 1, Jack S. Ocheltree 1, Jacob A. Galan 1,2, Emelyn Salazar 1 , Peter Davies 3 and Elda E. Sanchez 1,2 1 National Natural Toxins Research Center (NNTRC), Texas A&M University-Kingsville, MSC 224, 975 West Avenue B, Kingsville, TX 78363, USA; [email protected] (O.S.); [email protected] (A.R.); [email protected] (A.C.); [email protected] (J.S.O.); [email protected] (J.A.G.); [email protected] (E.S.); [email protected] (E.E.S.) 2 Department of Chemistry, Texas A&M University-Kingsville, MSC 161, Kingsville, TX 78363, USA 3 Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77843, USA; [email protected] * Correspondence: [email protected] Abstract: Cysteine-Rich Secretory Proteins (CRiSPs) are typically found in many snake venoms; however, the role that these toxins play in the pathophysiology of snakebites is still unclear. Herein, we compared the effects of snake venom CRiSPs (svCRiSPs) from the most medically important Citation: Suntravat, M.; Sanchez, O.; species of North American snakes on endothelial cell permeability and vascular permeability. We Reyes, A.; Cirilo, A.; Ocheltree, J.S.; used reverse phase protein array (RPPA) to identify key signaling molecules on human dermal Galan, J.A.; Salazar, E.; Davies, P.; lymphatic (HDLECs) and blood (HDBECs) endothelial cells treated with svCRiSPs.
    [Show full text]
  • NIH Public Access Author Manuscript J Control Release
    NIH Public Access Author Manuscript J Control Release. Author manuscript; available in PMC 2015 May 28. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Control Release. 2014 May 28; 0: 90–96. doi:10.1016/j.jconrel.2014.03.016. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model Jing Zhanga,c,1, Lei Miaoa,1, Shutao Guoa, Yuan Zhanga, Lu Zhanga, Andrew Satterleea, William Y. Kimb, and Leaf Huanga,* aDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA bLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA cKey Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330004, China Abstract Tumors grown in a stroma-rich mouse model resembling clinically advanced bladder carcinoma with UMUC3 and NIH 3T3 cells have high levels of fibroblasts and an accelerated tumor growth rate. We used this model to investigate the synergistic effect of combined gemcitabine monophosphate (GMP) nanoparticles and Cisplatin nanoparticles (Combo NP) on tumor- associated fibroblasts (TAFs). A single injection of Combo NP had synergistic anti-tumor effects while the same molar ratio of combined GMP and Cisplatin delivered as free drug (Combo Free) fell outside of the synergistic range. Combo NP nearly halted tumor growth with little evidence of general toxicity while Combo Free had only a modest inhibitory effect at 16 mg/kg GMP and 1.6 mg/kg Cisplatin.
    [Show full text]
  • Co-Stimulation of Purinergic P2X4 and Prostanoid EP3 Receptors Triggers Synergistic Degranulation in Murine Mast Cells
    International Journal of Molecular Sciences Article Co-Stimulation of Purinergic P2X4 and Prostanoid EP3 Receptors Triggers Synergistic Degranulation in Murine Mast Cells Kazuki Yoshida 1, Makoto Tajima 1, Tomoki Nagano 1, Kosuke Obayashi 1, Masaaki Ito 1, Kimiko Yamamoto 2 and Isao Matsuoka 1,* 1 Laboratory of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki-shi, Gunma 370-0033, Japan; [email protected] (K.Y.); [email protected] (M.T.); [email protected] (T.N.); [email protected] (K.O.); [email protected] (M.I.) 2 Department of Biomedical Engineering, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-27-352-1180 Received: 4 October 2019; Accepted: 16 October 2019; Published: 17 October 2019 Abstract: Mast cells (MCs) recognize antigens (Ag) via IgE-bound high affinity IgE receptors (Fc"RI) and trigger type I allergic reactions. Fc"RI-mediated MC activation is regulated by various G protein-coupled receptor (GPCR) agonists. We recently reported that ionotropic P2X4 receptor (P2X4R) stimulation enhanced Fc"RI-mediated degranulation. Since MCs are involved in Ag-independent hypersensitivity, we investigated whether co-stimulation with ATP and GPCR agonists in the absence of Ag affects MC degranulation. Prostaglandin E2 (PGE2) induced synergistic degranulation when bone marrow-derived MCs (BMMCs) were co-stimulated with ATP, while pharmacological analyses revealed that the effects of PGE2 and ATP were mediated by EP3 and P2X4R, respectively. Consistently, this response was absent in BMMCs prepared from P2X4R-deficient mice.
    [Show full text]
  • A Mouse Model Reproducing the Pathophysiology of Neonatal Group B Streptococcal Infection
    ARTICLE DOI: 10.1038/s41467-018-05492-y OPEN A mouse model reproducing the pathophysiology of neonatal group B streptococcal infection Elva Bonifácio Andrade 1,2,3,4, Ana Magalhães2,3, Ana Puga1, Madalena Costa1,4,5, Joana Bravo1,2,3, Camila Cabral Portugal2,3, Adília Ribeiro1,2,3, Margarida Correia-Neves6,7,8, Augusto Faustino1, Arnaud Firon 9, Patrick Trieu-Cuot9, Teresa Summavielle 2,3,4 & Paula Ferreira1,2,3 Group B streptococcal (GBS) meningitis remains a devastating disease. The absence of an 1234567890():,; animal model reproducing the natural infectious process has limited our understanding of the disease and, consequently, delayed the development of effective treatments. We describe here a mouse model in which bacteria are transmitted to the offspring from vaginally colo- nised pregnant females, the natural route of infection. We show that GBS strain BM110, belonging to the CC17 clonal complex, is more virulent in this vertical transmission model than the isogenic mutant BM110ΔcylE, which is deprived of hemolysin/cytolysin. Pups exposed to the more virulent strain exhibit higher mortality rates and lung inflammation than those exposed to the attenuated strain. Moreover, pups that survive to BM110 infection present neurological developmental disability, revealed by impaired learning performance and memory in adulthood. The use of this new mouse model, that reproduces key steps of GBS infection in newborns, will promote a better understanding of the physiopathology of GBS-induced meningitis. 1 ICBAS—Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, 4150-313 Porto, Portugal. 2 i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
    [Show full text]
  • Photomodulation of Lymphatic Delivery of Liposomes to the Brain Bypassing
    Nanophotonics 2021; 10(12): 3215–3227 Research article Oxana Semyachkina-Glushkovskaya*, Ivan Fedosov, Alexander Shirokov, Elena Vodovozova, Anna Alekseeva, Alexandr Khorovodov, Inna Blokhina, Andrey Terskov, Aysel Mamedova, Maria Klimova, Alexander Dubrovsky, Vasily Ageev, Ilana Agranovich, Valeria Vinnik, Anna Tsven, Sergey Sokolovski, Edik Rafailov, Thomas Penzel and Jürgen Kurths Photomodulation of lymphatic delivery of liposomes to the brain bypassing the blood-brain barrier: new perspectives for glioma therapy https://doi.org/10.1515/nanoph-2021-0212 singlet oxygen), we clearly demonstrate photostimulation Received May 3, 2021; accepted June 23, 2021; of lymphatic delivery of liposomes to glioma as well published online July 9, 2021 as lymphatic clearance of liposomes from the brain. These pilot findings open promising perspectives for Abstract: The blood-brain barrier (BBB) has a significant photomodulation of lymphatic delivery of drugs and contribution to the protection of the central nervous sys- nanocarriers to the brain pathology bypassing the BBB. tem (CNS). However, it also limits the brain drug delivery The lymphatic “smart” delivery of liposomes with and thereby complicates the treatment of CNS diseases. antitumor drugs in the new brain tumor branches might The development of safe methods for an effective delivery be a breakthrough strategy for the therapy of gliomas. of medications and nanocarriers to the brain can be a revolutionary step in the overcoming this limitation. Here, Keywords: glioma; liposomes; lymphatic backroad
    [Show full text]
  • Demonstration of a Neural Circuit Critical for Imprinting Behavior in Chicks
    The Journal of Neuroscience, March 24, 2010 • 30(12):4467–4480 • 4467 Development/Plasticity/Repair Demonstration of a Neural Circuit Critical for Imprinting Behavior in Chicks Tomoharu Nakamori,1,3 Katsushige Sato,2,4 Yasuro Atoji,5 Tomoyuki Kanamatsu,6 Kohichi Tanaka,1 and Hiroko Ohki-Hamazaki1,3,7 1Laboratory of Molecular Neuroscience, School of Biomedical Science and Medical Research Institute and 2Department of Physiology and Cell Biology, Faculty of Medicine, Graduate School, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan, 3Division of Biology, College of Liberal Arts and Sciences, Kitasato University, Sagamihara, Kanagawa 228-8555, Japan, 4Department of Health and Nutrition Sciences, Faculty of Human Health, Komazawa Women’s University, Inagi-shi, Tokyo 206-8511, Japan, 5Laboratory of Veterinary Anatomy, Faculty of Applied Biological Sciences, Gifu University, Gifu 501-1193, Japan, 6Department of Environmental Engineering for Symbiosis, Faculty of Engineering, Soka University, Hachioji, Tokyo 192-8577, Japan, and 7Recognition and Formation, Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan Imprinting behavior in birds is elicited by visual and/or auditory cues. It has been demonstrated previously that visual cues are recog- nized and processed in the visual Wulst (VW), and imprinting memory is stored in the intermediate medial mesopallium (IMM) of the telencephalon. Alteration of neural responses in these two regions according to imprinting has been reported, yet direct evidence of the neural circuit linking these two regions is lacking. Thus, it remains unclear how memory is formed and expressed in this circuit. Here, we present anatomical as well as physiological evidence of the neural circuit connecting the VW and IMM and show that imprinting training during the critical period strengthens and refines this circuit.
    [Show full text]
  • Sneaky Entry of Ifnγ Through Arsenic-Induced Leaky Blood–Brain Barrier Reduces CD200 Expression by Microglial Pro-Inflammatory Cytokine
    Molecular Neurobiology (2019) 56:1488–1499 https://doi.org/10.1007/s12035-018-1155-0 Sneaky Entry of IFNγ Through Arsenic-Induced Leaky Blood–Brain Barrier Reduces CD200 Expression by Microglial pro-Inflammatory Cytokine Vikas Singh1,2 & Shaivya Kushwaha1,2 & Ruchi Gera1,2 & Jamal Ahmad Ansari1,2 & Juhi Mishra3 & Jayant Dewangan4 & Satyakam Patnaik2,5 & Debabrata Ghosh1,2 Received: 13 January 2018 /Accepted: 25 May 2018 /Published online: 12 June 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Recent studies showed that neuronal surface protein CD200 plays a key role in the regulation of neuroinflammation. Previously, we showed that arsenic (0.38 mg/kg body weight) exposure induces microglial activation and consequently IL-6/TNF-α secre- tion. This result indicated the possibility of alteration in the expression of CD200. Therefore, the present study was focused on checking arsenic-induced alteration in CD200 expression and revealing the underlying mechanism. Male BALB/c mice were exposed to arsenic (vehicle, 0.038 and 0.38 mg/kg body weight) for 60 days, and the expression level of CD200 was found to be decreased which was rescued by minocycline (33 mg/kg body weight) co-administration. Higher CD68 staining, increased level of IL-6/TNF-α, as well as higher level of IFNγ, were observed in in vivo arsenic-exposed groups. Interestingly, in vitro arsenic exposure could not increase IL-6/TNF-α level in the culture supernatant, whereas, supplementation of IFNγ could mimic the in vivo results. However, arsenic could not induce IFNγ production from brain endothelial cells, microglia, and astrocytes, thereby suggesting the entry of IFNγ through the impaired blood–brain barrier.
    [Show full text]
  • Evans Blue Dye : a Revisit of Its Applications in Biomedicine
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Lirias Evans Blue Dye: A Revisit of Its Applications in Biomedicine Linpeng Yao1, Xing Xue1, Peipei Yu1,2, Yicheng Ni3, Feng Chen1* 1: Department of Radiology, The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou, 79 Qingchun Road, 310003, Zhejiang Province, China 2: Department of Radiology, Sanmen County People’s Hospital, Sanmen, 317100, Zhejiang Province, China 3: Radiology Section, University Hospitals, University of Leuven, Leuven, 3000, Belgium *Correspondence to: Feng Chen, MD, PhD Director, Department of Radiology, The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou, 79 Qingchun Road, 310003, Zhejiang Province, China Email: [email protected] Tel: +86 137 3558 9621 Keywords: Evans blue, necrosis, liposomal nanocarrier, theranostics, derivatives, enhanced permeability and retention (EPR) effect 1 Abstract Evans blue (EB) dye has owned a long history as a biological dye and diagnostic agent since its first staining application by Herbert McLean Evans in 1914. Due to its high water solubility and slow excretion, as well as its tightly binding to serum albumin, EB has been widely used in biomedicine, including its use in estimating blood volume and vascular permeability, detecting lymph nodes, and localizing the tumor lesions. Recently, a series of EB derivatives have been labeled with PET isotopes and can be used as theranostics with a broad potential due to their improved half-life in the blood and reduced release. Some of EB derivatives have even been used in translational applications in clinics. In addition, a novel necrosis-avid feature of EB has recently been reported in some preclinical animal studies.
    [Show full text]
  • ASM Abbreviations
    The words, abbreviations, and designations that follow are commonly encountered in ASM manuscripts. An asterisk (*) indicates that the abbreviation may be used (without introduction) with or without a numeral; however, the term should always be abbreviated in the bodies of tables. A double asterisk (**) indicates that the abbreviation must be used without introduction. “Need not be defined” means that the abbreviation does not have to be introduced, but it may be. “Hyphenated as unit modifier” means that the phrase is hyphenated when it is used adjectivally and precedes the noun it modifies; when it follows the noun, it should not be hyphenated: Gram-positive cells, BUT the cells were Gram positive. “Follow au.” means that ASM copy editors follow the author if one of the alternative forms is used consistently throughout the manuscript; otherwise, the copy editor will choose one form and be consistent. At times, your definition for an abbreviation may vary significantly from the one given here. Generally, ASM copy editors will follow the author, especially if the term is a chemical name that can be verified. If the variation is slight, however (e.g., hyphens, spacing), the copy editor will follow this manual. You may find helpful medical acronym websites like https://www.medindia.net/medical-abbreviations-and- acronyms/index.asp and https://www.medilexicon.com/abbreviations. As a general rule, use the specific abbreviations given in this list: PFU, NOT pfu; i.p., NOT IP; cpm, NOT CPM; IFN, NOT IF. For abbreviations that do not appear in this manual, periods and all-lowercase abbreviations should be avoided.
    [Show full text]
  • University of Cincinnati
    UNIVERSITY OF CINCINNATI Date: 10-Nov-2009 I, Keith J Gaddie , hereby submit this original work as part of the requirements for the degree of: Doctor of Philosophy in Molecular, Cellular & Biochemical Pharmacology It is entitled: Structural Elements that Regulate Interactions between the Extracellular and Transmembrane Domains of Human Nucleoside Triphosphate Student Signature: Keith J Gaddie This work and its defense approved by: Committee Chair: Terence Kirley, PhD Terence Kirley, PhD Scott Belcher, PhD Scott Belcher, PhD Paul Rosevear, PhD Paul Rosevear, PhD John Maggio, PhD John Maggio, PhD Ronald Millard, PhD Ronald Millard, PhD 11/23/2009 294 Structural Elements that Regulate Interactions between the Extracellular and Transmembrane Domains of Human Nucleoside Triphosphate Diphosphohydrolase 3 A dissertation submitted to the Division of Research and Advanced Studies of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY (Ph.D.) in the Department of Pharmacology and Cell Biophysics of the College of Medicine 2009 By Keith J. Gaddie B.S. Fisk University, 2003 Committee Chairperson: Terence L. Kirley, Ph.D. Abstract The nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of constitutively expressed, endogenous nucleotidases, some of which regulate purinergic signaling by divalent cation-dependent hydrolysis of nucleotides acting as agonists at purinergic receptors. Due to the scarcity of specific inhibitors and genetically modified animals, the functions of most individual NTPDases are poorly understood and still under investigation. However, the NTPDases have been implicated in many biological and physiological processes, including secretion, cell adhesion, pain perception, cancer and malignant transformation, adenosine recycling, and platelet aggregation.
    [Show full text]
  • ABSTRACT EVANS, MATTHEW RICHARD. Global Effects of The
    ABSTRACT EVANS, MATTHEW RICHARD. Global Effects of the Transcriptional Regulators ArcA and FNR in Anaerobically Grown Salmonella enterica sv. Typhimurium 14028s. (Under the direction of Dr. Hosni M. Hassan.) The purpose of this research was to assess and compare the genome-wide transcriptional profiles and virulence in mice of the global regulators, FNR (Fumarate Nitrate Reductase) and ArcA (Aerobic Respiratory Control) in anaerobically grown Salmonella enterica serovar Typhimurium 14028s. FNR controls the expression of target genes by sensing and responding to the presence or absence of dioxygen via assembly-disassembly of oxygen-liable iron-sulfur clusters, while ArcA is a two-component (ArcA/ArcB), cytosolic redox response regulator. This work demonstrates that FNR is a positive regulator of motility, flagellar biosynthesis, and pathogenesis. An fnr mutant was non- motile, lacked flagella, attenuated for virulence in mice, and did not survive inside macrophages. In S. Typhimurium, as in Escherichia coli, the FNR modulon encompassed the core metabolic and energy functions as well as motility. Salmonella-specific genes/operons regulated by FNR included those required for ethanolamine utilization, newly identified flagellar genes (mcpAC, cheV), several virulence genes in Salmonella pathogenicity island 1 (SPI-1), and the srfABC operon. ArcA serves as a transcriptional repressor/activator coordinating cellular metabolism and motility. An arcA mutant was non-motile, lacked flagella, and was as virulent as the wild-type strain via intraperitoneal challenge in mice. In S. Typhimurium, as in E. coli, the ArcA modulon encompassed the core metabolic and energy functions as well as motility. Salmonella-specific genes/operons regulated by ArcA included those for propanediol utilization, newly identified flagellar genes (mcpAC, cheV), Gifsy- 1 prophage genes, and a few virulence genes located in SPI-3 (mgtBC, slsA, STM3784).
    [Show full text]